<DOC>
	<DOCNO>NCT02586207</DOCNO>
	<brief_summary>This single-arm , multi-site , open-label trial pembrolizumab ( MK-3475 ) use combination standard , cisplatin-based , definitive chemoradiotherapy ( CRT ) patient stage III-IVB squamous cell carcinoma head neck ( SCCHN ) . Approximately 39 patient Stage III-IVB SCCHN enrol evaluate safety efficacy novel combination . Subjects randomize receive study treatment . Treatment consist load dose pembrolizumab 200 mg IV give 7 day prior initiation CRT ( day-7 ) . CRT cisplatin 40 mg/m2 IV weekly head neck radiation 70 Gy fractionate 2 Gy daily 35 day , begin day 1 . CRT end approximately day 46-50 . Pembrolizumab 200 mg IV continue follow CRT adjuvant fashion start day 57 additional 5 dos , tolerate , day 141 . Subjects evaluate response follow treatment .</brief_summary>
	<brief_title>Pembrolizumab Combination With CRT LA-SCCHN</brief_title>
	<detailed_description>Each subject participate trial time subject sign Informed Consent Form ( ICF ) final protocol-specified contact . After screen phase 28 day , eligible subject receive treatment Day -7 load dose study drug . This continue concurrent therapy cisplatin radiation , begin day 1 . Treatment continue completion therapy , document confirmed disease progression , unacceptable adverse event ( ) , intercurrent illness prevents administration treatment , investigator 's decision withdraw subject , subject withdraws consent , pregnancy patient , noncompliance trial treatment procedure requirement ; administrative reason . After end treatment , patient follow 30 day adverse event monitoring ( serious adverse event collect 90 day end treatment 30 day end treatment patient initiate new anticancer therapy , whichever early ) . Subjects discontinue reason disease progression post-treatment follow-up disease status end study disease progression , initiate non-study cancer treatment , withdraw consent , become lose follow-up . All subject follow telephone overall survival death , withdrawal consent , Investigator notify Sanford Research discontinue follow-up</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Have histologically cytologicallyconfirmed head neck squamous cell carcinoma oral cavity ( exclude lip ) , oropharynx , hypopharynx , larynx . 2 . Have TNM clinical stage III , IVA , IVB disease 3 . Be eligible curativeintent concurrent chemoradiation therapy 4 . Be willing able provide write informed consent trial . 5 . Be 18 year age day sign informed consent . 6 . Have measurable disease base RECIST 1.1 . 7 . Be willing provide tissue recently obtain core excisional biopsy tumor lesion . Newlyobtained defined specimen obtain 6 week ( 42 day ) prior initiation treatment Day 7 . Subjects newlyobtained sample provide ( e.g . inaccessible subject safety concern ) may submit archived specimen upon agreement Sanford Research . 8 . Have performance status 0 1 ECOG Performance Scale . 9 . Demonstrate adequate organ function define : Absolute neutrophil count ( ANC ) ≥1,500 /mcL Platelets ≥100,000 / mcL Hemoglobin ≥9 g/dL ≥5.6 mmol/L without transfusion EPO dependency ( within 7 day assessment ) Serum creatinine OR Measured calculate creatinine clearance ( GFR also use place creatinine CrCl ) ≤1.5 X upper limit normal ( ULN ) OR ≥60 mL/min subject creatinine level &gt; 1.5 X institutional ULN Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN subject total bilirubin level &gt; 1.5 ULN AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 X ULN OR ≤ 5 X ULN subject liver metastasis Albumin &gt; 2.5 mg/dL 10 . Female subject childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . 11 . Female subject childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Subjects childbearing potential surgically sterilize free menses &gt; 1 year . 12 . Male subject agree use adequate method contraception start first dose study therapy 120 day last dose study therapy . 1 . Patients may receive investigational agent , chemotherapy , immunotherapy , radiotherapy , molecular target agent within 4 week start study treatment . 2 . Prior treatment radiation head neck 3 . Patients TNM Stage IVC disease 4 . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose treatment . 5 . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . 6 . Has know history active TB ( Bacillus Tuberculosis ) 7 . Hypersensitivity pembrolizumab excipients . 8 . Has prior anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . 9 . Has prior chemotherapy , target small molecule therapy , radiation therapy . 10 . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer . 11 . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . 12 . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( eg. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . 13 . Has know history , evidence active , noninfectious pneumonitis . 14 . Has active infection require systemic therapy . 15 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 16 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 17 . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120days last dose trial treatment . 18 . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent . 19 . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . 20 . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . 21 . Has receive live vaccine within 30 day plan start study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Larynx</keyword>
	<keyword>Squamous Cell</keyword>
	<keyword>Oral cavity</keyword>
	<keyword>Oropharynx</keyword>
	<keyword>Hypopharynx</keyword>
</DOC>